Johnson & Johnson is expected to aggressively promote Rybrevant (amivantamab-vmjw) following the US Food and Drug Administration’s rapid approval of the drug for a rare subset of non-small cell lung cancer (NSCLC). While Rybrevant may also have a place among NSCLC patients relapsing on AstraZeneca PLC’s Tagrisso (osimertinib), its safety and tolerability profile may place limitations on its uptake, potentially creating an opening for a competing drug in earlier development by Cullinan Oncology, Inc..
The FDA granted accelerated approval of Rybrevant on 21 May for locally advanced or metastatic NSCLC with EGFR exon 20...






